checkAd

     294  0 Kommentare Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin Litigation - Seite 2

    Investor Relations for Eagle Pharmaceuticals, Inc.:

    Lesen Sie auch

    Lisa M. Wilson
    In-Site Communications, Inc.
    T: 212-452-2793
    E: lwilson@insitecony.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 2 von 2
    Verfasst von globenewswire
    Federal Circuit Rules in Favor of Eagle Pharmaceuticals in Vasopressin Litigation - Seite 2 WOODCLIFF LAKE, N.J., Aug. 18, 2022 (GLOBE NEWSWIRE) - Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District …